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Abstract
The presence of antimicrobial peptides (AMPs) in saliva may be a biological factor that contributes
to susceptibility or resistance to caries. This manuscript will review AMPs in saliva, consider their
antimicrobial and immunomodulatory functions, and evaluate their potential role in the oral cavity
for protection of the tooth surface as well as the oral mucosa. These AMPs are made in salivary
gland and duct cells and have broad antimicrobial activity. Alpha-defensins and LL37 are also
released by neutrophils into the gingival crevicular fluid. Both sources may account for their
presence in saliva. A recent study in middle school children aimed to determine a possible
correlation between caries prevalence in children and salivary concentrations of the antimicrobial
peptides human beta-defensin-3 (hBD-3), the cathelicidin, LL37, and the alpha-defensins. The levels
of these AMPs were highly variable in the population. While levels of LL37 and hBD-3 did not
correlate with caries experience, the mean alpha-defensin level was significantly higher in children
with no caries than in children with caries (p < 0.005). We conclude that several types of AMPs
that may have a role in oral health are present in unstimulated saliva. Low salivary levels of alpha-
defensin may represent a biological factor that contributes to caries susceptibility. Our observation
could lead to new ways to prevent caries and to a new tool for caries risk assessment.
Introduction
The oral cavity is a unique environment. Oral mucosae are
a critical protective interface between external and inter-
nal environments and must serve as a barrier to the myr-
iad microbial species present in the mouth. Saliva, the
epithelial surface layers, and polymorphonuclear leuko-
cytes (neutrophils) all contribute to maintaining the
health of the oral cavity and periodontium in overlapping
but independent ways (Figure 1). Antimicrobial peptides
(AMPs) are natural antibiotics that are found in each of
these compartments: in the saliva, in the epithelium, and
in neutrophils. Evidence is accumulating that AMPs are
important contributors to maintaining the balance
between health and disease as part of the host innate
immune response. They have generally been considered
to contribute to mucosal health; however, it is logical that
these AMPs are biological factors that influence caries sus-
ceptibility and development as well.
This manuscript will review oral AMPs, consider their role
as genetically inherited factors that may be among the bio-
logical controls that influence caries risk, briefly describe
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a study of AMPs in children with and without caries, and
discuss the potential utility of one particular AMP in caries
risk assessment and prevention.
Oral AMPs and caries
Oral AMPs provide a first line of defense against a wide
spectrum of pathogens [1-3]. Members of the three main
AMP families are found in the oral cavity. These are
defined by biochemical and structural characteristics: 1)
α-helical peptides without cysteine (the cathelicidin,
LL37) [4]; 2) peptides with three disulphide bonds (the α-
and β- defensins) [1,5]; and 3) peptides with an unusually
high proportion of specific amino acids; for example, the
histatins [6].
Recent research suggests the importance of the defensins
and the cathelicidin LL37 as antibacterial agents in the
oral cavity [7], while histatins are primarily antifungal
agents [6]. The human β-defensins (hBDs) are widely
expressed in oral tissues including gingival epithelium
[8,9], salivary glands and ducts and saliva [10,11]. The
neutrophil alpha-defensins, (human neutrophil peptides
1–3 (HNP1–3)), are one of the mechanisms for non-oxi-
dative microbial killing [5] and are found in gingival cre-
vicular fluid [12]. The human cathelicidin peptide, LL37,
is in neutrophils, inflamed epithelia, submandibular sali-
vary glands and saliva [13,14].
With antimicrobial peptides now strongly implicated in
the host innate immune response, in particular in the oral
cavity (reviewed by Dale and Fredericks, Ganz) [7,1], their
availability in unstimulated saliva implies their potential
role in protecting tooth structure from bacterially-induced
caries, either by direct killing or by prevention of biofilm
formation on the tooth surface.
The defensins and cathelicidin have broad antimicrobial
activity against gram-negative and gram-positive bacteria
and are effective against oral microorganisms such as
Streptococcus mutans, Porphyromonas gingivalis and Actino-
bacillus actinomycetemcomitans [7,15-19]. The expression
and major activities of AMPs in saliva are summarized in
Table 1; however it should be noted that these peptides
have both species and strain specificity, for unknown rea-
sons, and it is difficult to generalize their antimicrobial
function. The cathelicidins and defensins act synergisti-
cally with other antimicrobials [20,21]. Thus, the co-
expression in saliva of LL37 and defensins with peptides
such as histatin, proline-rich proteins, and calprotectin
may provide a natural antibiotic barrier.
Genetic influences on AMP expression and on 
caries
The amount of AMPs expressed in saliva varies between
individuals. This has been previously demonstrated for
alpha- and beta-defensins, histatin, and proline-rich pro-
teins [6,22,23]. Our initial studies in children show that
the levels of these peptides in unstimulated saliva vary
greatly between individuals, even when differences in
total salivary protein are considered (see below). The large
variation in concentration of defensins in saliva and in
their mRNA in oral tissues could be attributed to the
organization of their genes. The genes for the alpha- and
beta-defensins lie in a cluster on human chromosome 8.
Several genes in this region can occur as multiple repeated
copies. This is known as copy number polymorphism
[24,25]. We do not yet know if individuals with multiple
copies of a particular gene, for example, HNP1, make
more of the protein, but this seems quite likely. In other
words, individual differences in the amount of alpha- and
Diagram indicating the presence of antimicrobial peptides in  saliva (blue), in gingival epithelium (pink), and in neutrophils  (PMNs) migrating into the oral cavity via the gingival crevicu- lar fluid Figure 1
Diagram indicating the presence of antimicrobial peptides in 
saliva (blue), in gingival epithelium (pink), and in neutrophils 
(PMNs) migrating into the oral cavity via the gingival crevicu-
lar fluid. All of these sources of antimicrobial peptides may 
aid protection of the mucosa from bacterial infection and the 
tooth surface from caries.BMC Oral Health 2006, 6:S13
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beta-defensins may be genetically determined. In contrast,
there is only one copy of the LL37 gene, which is located
on chromosome 3.
There is also evidence for genetically determined factors in
susceptibility to caries. Anecdotal evidence suggests indi-
vidual differences in caries experience in children even
within the same family [26]. These individual differences
suggest that biological factors, which may be genetically
determined, have a role in caries resistance and suscepti-
bility. Studies of twins offer the strongest evidence to date
for the importance of biologically inherited factors con-
tributing to caries susceptibility [27-29]. Twins show sig-
nificantly greater similarity of caries experience in
monozygotic (MZ, identical) than in dizygotic (DZ, frater-
nal) twins (reviewed by Shuler) [30].
Salivary proteins and caries experience
Salivary constituents are potential candidates as biological
factors influencing caries risk. Many salivary protein com-
ponents, such as proline-rich glycoprotein, mucins,
immunoglobulins, agglutinin, lactoferrin, cystatins and
lysozyme are thought to have a role in defense in the oral
cavity [31]. Numerous studies have investigated the corre-
lation among these salivary proteins and glycoproteins
and caries experience, but no studies have shown reliable
association between a single salivary component and car-
ies experience [32,33]. The expression of AMPs in saliva
and throughout the oral cavity suggests that they may
have a role in protecting tooth structure from caries as
well as protecting oral mucosa. Several reasons for this
proposal are 1) AMPs have broad antimicrobial activity;
2) their action is synergystic with other antimicrobials in
saliva; co-expression of cathelicidins and defensins with
peptides such as histatin, proline-rich proteins may
enhance antimicrobial function; 3) they stimulate the
acquired immune system and could function to enhance
IgA production as well as IgG production [2]; 4) these
AMPs may function to keep overall bacteria in check and
to help prevent biofilm formation. Thus, oral AMPs may
provide a natural antibiotic barrier.
AMPs and caries in middle school children
To investigate the possible relationship between AMP lev-
els in saliva and caries experience, we conducted a study
in middle school children located in a rural area in Wash-
ington state [34]. One hundred and forty-nine children
(88 females, 61 males) participated in the study. All chil-
dren were between 11 and 15 years of age. Most of the
population was Hispanic with some Native Americans
and Caucasians. A brief health history survey was com-
pleted by parents of the subjects. Oral examinations were
performed by trained calibrated clinicians using standard-
ized procedures. Overall, the children were healthy with
92% having no history of major illness or disease. The
study was conducted with permission of school officials
and informed consent of subjects and parents obtained
through an educational session and written bilingual con-
sent in accordance with a protocol approved by the Uni-
versity of Washington Institutional Review Board. A brief
health history was taken, and unstimulated saliva samples
collected and stored in a frozen state for later analysis.
Examiners were instructed to rank subjects separately for
active caries and for filled surfaces as 0, no decayed or
filled surfaces; 1, mild (1–2 affected surfaces); 2, moderate
(3–6 affected surfaces); and 3, severe (>6 affected sur-
faces). Final caries experience score was determined as the
sum of the scores for active decay and filled surfaces. Fifty-
three subjects (36%) had no decay, 37 (24%), 39 (27%),
and 20 (13%) had caries scores of 1, 2, and 3 or greater,
respectively.
For analysis, saliva samples were thawed and cleared by
centrifugation twice at 15,000 rpm for 10 min. Cleared
saliva samples were assayed for total protein concentra-
tion by the BCA assay (Pierce Inc., Rockford, IL, USA) and
Table 1: Antimicrobial Peptides in Saliva
Peptide Origin Role/comments Major Oral Microbial 
Targets
References
Alpha-defensins HNP 1–4 Neutrophils, gingival sulcus, 
sites of inflammation, 
salivary duct cells
Antibacterial, antifungal, 
antiviral. Present in GCF
Candida albicans HIV S. 
mutans (poor)
(Raj et al., 2000; Zhang et 
al., 2002) [43, 44]
LL-37 Neutrophils, gingival sulcus, 
salivary glands and ducts
Primarily antibacterial S. mutans F. nucleatum A. 
actinomycetemcomitans 
Capnocytophaga sputigena
(Ouhara et al., 2005; 
Tanaka et al., 2000) [17, 19]
Beta-defensins hBD1 hBD2 
hBD3
Epithelia, salivary ducts Antibacterial, antifungal, 
antiviral. Part of the 
protective barrier function 
of epithelium. Secreted
hBD1: Poor antibacterial 
hBD2, hBD3: S. mutans S. 
sanguis F. nucleatum P. 
gingivalis Candida albicans 
HIV
(Joly et al., 2004; Maisetta 
et al., 2003; Quinones-
Mateu et al., 2003)[15, 20, 
18]
Histatins Salivary glands/ducts Antifungal Candida albicans (Oppenheim et al., 1988) 
[6]BMC Oral Health 2006, 6:S13
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for alpha-defensin HNP1–3 ELISA assay according to
manufacturer's instructions (HyCult Biotechnology,
Uden, Netherlands). This assay measures HNP1, 2, and 3
because the antibody does not distinguish between these
closely related peptides. Aliquots of cleared saliva were
acid-extracted for assay of LL37 and hBD3 by slot immu-
noblot analysis (LL37 by assay from Phoenix Pharmaceu-
ticals Inc., Belmont, CA and hBD3 using polyclonal
antibody from Orbigen Inc, San Diego, CA). The mean
protein concentration of unstimulated saliva samples was
1633 ± 908 µg/ml (range from 421 to 7052 µg/ml). This
value agrees with previously reported total protein con-
centration for this age group [35]. The salivary protein
concentration showed no correlation with age, gender, or
caries score. Antimicrobial peptide (AMP) concentrations
were in the µg/ml range. AMP levels were also normalized
to the protein concentration in whole saliva for each sam-
ple. HNP1–3, hBD3 and LL37 all showed extensive varia-
tion in concentration in our population, even when
normalized to total salivary protein levels. Mean values
for HNP1–3, hBD3 and LL37 were 0.94, 0.73, 3.36 µg/ml,
respectively, with the range extending 10-fold up and
down from the mean. The concentration of AMPs in
unstimulated saliva of children has not been previously
reported, although normal adults have a mean value of
0.8 µg/ml HNP [36].
When the relationship of AMP expression and caries expe-
rience was evaluated, we found a significant difference in
the level of HNP1–3 among different caries groups (p <
0.005). Differences were observed for both the mean (or
median) level of salivary HNP1–3 concentration (µg/ml)
and salivary HNP1–3 relative to salivary protein (µg/mg).
The HNP1–3 concentration was 1.30 ± 0.22 µg/ml
(median ± std. error of the mean) for the caries free group
(n = 51) and 0.73 ± 0.07 µg/ml for all subjects with evi-
dence of caries (n = 92) (independent sample two tailed T
test, p = 0.005). The HNP1–3 value relative to total sali-
vary protein was 0.84 ± 0.14 µg/mg protein in the caries
free group and 0.48 ± 0.05 µg/mg protein in the com-
HNP 1–3 concentration in saliva as a function of caries score Figure 2
HNP 1–3 concentration in saliva as a function of caries score. The HNP1–3 peptides are closely related and are all detected by 
the immunoassay used. Note statistically significant difference between the caries groups and the 0 Caries group; * p < 0.05; 
*** p < 0.005.BMC Oral Health 2006, 6:S13
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bined caries group (p = 0.005) (Figure 2). Similar analysis
for LL37 showed the same trend with higher levels of LL37
in the no caries group than in those with caries, but results
were not statistically significant. HBD3 concentration in
saliva and the level of hBD3 relative to protein showed no
significant difference in our population or between the
different caries groups (not shown). Statistical analyses
were also done using the Kruskal-Wallis non-parametric
test based on rank and designed for non-normally distrib-
uted data. Using this test, significance differences were
verified or even improved. We also evaluated whether
association with caries could be due to either HNP1–3 or
LL37, but over 90% of the effect was due to HNP1–3.
Finally, to further examine the relationship of HNP1–3
with caries, the HNP concentration values were divided
into quartiles and evaluated for subjects with no caries
compared to those with caries (Table 2). An increasing
proportion of subjects had no caries as the HNP concen-
tration increased; only 14% of the subjects with HNP1–3
levels of < 0.4 µg/ml (n = 36) were caries free, but 55% of
the subjects with HNP1–3 levels greater than 1.08 µg/ml
(n = 36) were caries free. It can be readily seen that chil-
dren with low salivary alpha-defensin have greater levels
of caries.
There were two major findings from our study. First, there
was extensive variation in AMP levels between individu-
als; levels varied by 100 fold from the lowest to highest
even when adjusted for total salivary protein. Second, the
level of alpha-defensins HNP1–3 was inversely correlated
with caries (Figure 2). Our findings suggest that low sali-
vary levels of HNP1–3 may contribute to caries suscepti-
bility and could be a new and useful measure of the risk
for caries in children.
Where do the salivary HNPs and other AMPs 
come from?
The most obvious source for salivary AMPs is secretion by
salivary gland and duct cells. LL-37 and beta-defensins are
expressed in salivary glands [7,8,10,13,14]. In addition,
we have shown HNP1–3 by immunohistochemistry in
submandibular salivary duct cells [34]. The submandibu-
lar glands are the major source of unstimulated saliva,
suggesting that these cells may be a source of AMPs in
saliva. However, an important alternative source for
HNP1–3 and LL37 are the neutrophils that migrate into
the oral cavity via gingival crevicular fluid. In normal indi-
viduals it has been estimated that 30,000 neutrophils per
minute enter the oral cavity via this route through the
junctional epithelium surrounding the teeth [37]. This
flow of neutrophils is required for periodontal health, and
defects in neutrophil function and chemotatsis are associ-
ated with early onset periodontal disease in children
[38,39]. Our findings suggest that this flow of neutrophils
may also be important for protection from caries.
How does HNP provide protection?
HNP1–3 in saliva could contribute to resistance to caries
by direct antimicrobial properties (either alone or in com-
bination with other saliva components) or by preventing
biofilm formation on the surface of the tooth via its ability
to bind bacterial outer membranes. The AMP levels found
in saliva in this study are in the range of effective antimi-
crobial function for beta-defensins vs. S. mutans [17]
although effectiveness of HNPs against S. mutans has not
been reported. The low ionic strength in saliva is condu-
cive to antimicrobial activity and thus may impact the
flora of the oral cavity and exert a beneficial effect on den-
tal health. In addition, alpha- and beta-defensins as well
as LL37 have other immunomodulatory and chemoat-
tractant effects, and individuals with high expression may
benefit from these effects. The inverse correlation of
HNP1–3 with caries experience suggests its possible pro-
tective effect. Conversely, low levels of HNP1–3 may
result in increased susceptibility to caries.
Conclusion
We have many follow-up questions. Based on our study
design, we cannot yet determine if the level of salivary
alpha-defensin is predictive of future caries, but we have
shown that children with caries have significantly lower
levels of alpha-defensins based both on their concentra-
tion in saliva and their relationship to total salivary pro-
tein. Can this finding be replicated in younger children?
This is important because of the need for new approaches
for caries risk assessment in young children, when preven-
tive measures are likely to have the greatest impact. Iden-
Table 2: Caries Free Children by HNP score
HNP µg/ml n Caries Free (n) Caries Free (%)
0.06–0.39 36 5 14%
0.40–0.60 36 12 33%
0.60–1.03 36 14 39%
1.08–10.5 36 20 55%
Total pop. 144 51 35%BMC Oral Health 2006, 6:S13
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tifying those children who are at highest risk for disease
will enable limited resources to be targeted toward indi-
vidualized, aggressive and pro-active interventions to pre-
vent caries. Can the level of AMPs be replicated over time?
Could alpha-defensins be used therapeutically or in a pro-
spective manner in mouthwash or toothpaste or chewing
gum? Is the effect primarily an antimicrobial effect, or is it
also due to immunomodulatory functions of these pep-
tides? Do children with very low alpha-defensin levels
have different flora than children with high alpha-
defensin levels? Is there a relationship between the inten-
sity of tooth brushing and levels of salivary AMPs? Per-
haps vigorous brushing could stimulate outflow of the
neutrophils via the gingival sulcus. In addition, the junc-
tional epithelium is innervated with substance P express-
ing nerve fibers. Irritation provoked by vigorous brushing
might stimulate local release of this neuropeptide, which
in turn has profound chemoattractive activity for neu-
trophils [40,41].
The prediction of caries risk has been of long-standing
interest and is very important for development of new pre-
ventive strategies. This is especially significant for young
children and for children with special health care needs.
Saliva is an easily available fluid which can be collected
non-invasively and used to measure and monitor the risk
for caries [42]. The assay for HNP1–3 is easy to perform
and can be done using less than 0.2 ml crude whole saliva.
Low salivary levels of alpha-defensins (HNP1–3) could be
a new and useful measure of the risk for caries in children.
Future studies could lead to development of means to
enhance endogenous oral peptide expression, to utiliza-
tion of these peptides as therapeutics, and to the develop-
ment of a simple test for clinical evaluation of caries risk.
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